Australia's CSL to invest A$235 million in biotech manufacturing facility

16 July 2010

Australia's CSL announced a major biotechnology project at its manufacturing site in Broadmeadows, Victoria, involving a total investment of A$235 million ($205.6 million) over four to five years, which includes a A$30 million contribution from the federal government.

The centerpiece of the project will be the creation of Victoria's first large scale biotechnology facility for the late-stage development of new therapies for cancer, bleeding disorders, inflammation and infection.

'Our world-class R&D portfolio contains promising life-saving therapies for a range of serious human diseases. This new facility will enable CSL to develop innovative products for clinical trials and future patient use,' said the company's chief executive Brian McNamee.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK